The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict National Research's revenues will expand 12.0% and EPS will contract 0.0%.
The average estimate for revenue is $23.1 million. On the bottom line, the average EPS estimate is $0.16.
Last quarter, National Research logged revenue of $24.9 million. GAAP reported sales were 11% higher than the prior-year quarter's $22.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, EPS came in at $0.18. GAAP EPS of $0.18 for Q1 were 13% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 58.9%, 120 basis points worse than the prior-year quarter. Operating margin was 29.0%, 190 basis points better than the prior-year quarter. Net margin was 17.9%, 70 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $97.5 million. The average EPS estimate is $0.69.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 113 members out of 119 rating the stock outperform, and six members rating it underperform. Among 39 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give National Research a green thumbs-up, and two give it a red thumbs-down.
Is National Research the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add National Research to My Watchlist.